Healthy Lifestyle Intervention in Patients With Systemic Lupus Erythematosus: The Living Well With Lupus Study
Primary Purpose
Systemic Lupus Erythematosus
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Living well with Lupus
Sponsored by
About this trial
This is an interventional treatment trial for Systemic Lupus Erythematosus focused on measuring Life style, Behavioral intervention, Cardiovascular risk, Life quality
Eligibility Criteria
Inclusion Criteria:
- Women between 18 and 65 years old diagnosed with systemic lupus erythematosus
- one or more high cardiovascular risk factors
- SLEDAI score ≤ 4
- Treatment with prednisone at a dosage <10 mg/d and treatment with hydroxychloroquine in a stable dose
Exclusion Criteria:
- another rheumatic diseases (except for secondary Sjogren's syndrome)
- participation in structured exercise training programs and/or prescriptive diets
- illiterate or with diagnosed cognitive disorders or musculoskeletal impairments that potentially compromise understanding and participation in the intervention
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Living well with Lupus Group
Usual Care Group
Arm Description
A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
This group will receive all regular medical care and advice healthy
Outcomes
Primary Outcome Measures
Risk cardiovascular score
assessed by measures of five standard variables (HDL cholesterol, triglycerides, fasting blood glucose, waist circumference and blood pressure - average of systolic and diastolic blood pressures). Z-score = [(50 - HDL cholesterol)/sd + (triglycerides - 150)/ sd] + [(fasting blood glucose - 100)/ sd] + [(waist circumference - 88)/ sd] + [(blood pressure - 115)/ sd]. Higher score values represent higher risk. *sd: standard deviation. Higher Z-score represent higher risk.
Secondary Outcome Measures
Body mass index (BMI)
assessed by weight (kg) and height (m) that will be combined to report BMI in kg/m^2
Waist circumference (cm)
assessed by measuring tape positioned at the midpoint between the last floating vertebra and the iliac crest.
Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides
assessed by blood sample analysis and combined to determine lipid profile
Insulin sensitivity
assessed by oral glucose tolerance test (OGTT)
Systolic and Diastolic blood pressure
assessed by auscultatory method with mercury sphygmomanometer
Physical activity level
assessed by thigh-mounted accelerometer (ActivPAL™ micro)
Food consumption
assessed by three 24-hour food recall in non-consecutive days (being one of the days on the weekend)
Visceral fat
assessed by tomography
Peak oxygen consumption, as assessed by a cardiopulmonary exercise test
Endothelial function
assessed by flow-mediated vasodilatation (FMD)
Disease activity
The activity of the disease, which will be impaired by safety, will be assessed by the presence of anti-dsDNA, using the ELISA technique and confirmation by indirect immunofluorescence in Crithidia luciliae and assessed by the questionnaire Systemic lupus erythematosus disease activity index 2000 (SLEDAI-2000). Total score ranges from 0 to 105. Higher scores represent higher disease activity.
Damage index
assessed by Systemic Lupus International Collaborating Clinics/ American College of Rheumatology - Damage Index. Total score range from 0 (no damage) to 46 (maximum damage).
Global health status
assessed by the Visual Analogic Scale (0 and 10 scale). Higher values represent worst global health status.
Patients' perceptions of the intervention
assessed by focus group. A semi-structured script composed of open questions about intervention positive and negative points, barriers for physical activity practice and changes in food consumption, perceptions of health improvement or worsening (physical and psychological aspects), well-being, motivation to maintain the changes made, perspectives regarding health and disease.
Quality of Life assesment assessed by the Short-Form Health Survey-36 (SF36) [followed by its scale information in the Description]
maximum score is 100, with higher scores representing better life quality
Quality of Life assessed by Systemic Lupus Erythematosus Quality of Life Questionnaire ( SLEQOL) [followed by its scale information in the Description]
score ranges from 40 to 280 with higher scores represent worst life quality.
Physical functioning assessed by Timed-Stands
evaluates the maximum number of stand-ups that a subject could perform from a standard height (i.e., 45 cm) armless chair within 30 s
Physical functioning assessed by Timed Up-and-Go
evaluates the time required for the subject to rise from a standard arm chair, walk towards a line drawn on the floor three meters away, turn, return, and sit back down again
Physical functioning assessed by handgrip test
Patients will be instructed to squeeze the dynamometer as hard as possible
Fatigue
assessed by Fatigue Scale (FACIT). The final score can vary from 0 to 52, where higher final score representing higher level of fatigue.
Anxiety
assessed by sub-scale of Hospital Anxiety and Depression Scale (HADS), called HADS-A. Total score ranges from 0 to 21. Where higher final score representing higher level.
Depression
assessed by sub-scale of Hospital Anxiety and Depression Scale (HADS), called HADS-D. Total score ranges from 0 to 21. Where higher final score representing higher level.
Sleep quality assessed by data obtained from Actigraph (Actigraph GT3x)
Data from actigraph will come as these measures: Total Sleep Time (hours/day), Sleep Efficiency (%), Sleep Onset Latency (min), and Wake After Sleep Onset (min), and this data will be considered to determine the sleep quality.
C-reactive protein (PCR)
assessed by analysis of blood sample
Erythrocyte sedimentation rate
assessed by analysis of blood sample
Inflammatory markers (blood biochemistry)
assessed by serum cytokines
Full Information
NCT ID
NCT04431167
First Posted
February 18, 2020
Last Updated
June 10, 2020
Sponsor
University of Sao Paulo
1. Study Identification
Unique Protocol Identification Number
NCT04431167
Brief Title
Healthy Lifestyle Intervention in Patients With Systemic Lupus Erythematosus: The Living Well With Lupus Study
Official Title
Healthy Lifestyle Intervention in Patients With Systemic Lupus Erythematosus With High Cardiovascular Risk: The Living Well With Lupus Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2020 (Anticipated)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
December 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This research program aims to investigate the clinical, physiological, metabolic and molecular effects of lifestyle change in patients with systemic lupus erythematosus with high cardiovascular risk. This 6-month parallel-group randomized controlled trial aims to investigate the feasibility and efficacy of a newly developed lifestyle change intervention - through recommendations for structured and unstructured physical activity and healthy eating - on increasing physical activity level and improving eating habits. Potential effects of the intervention on cardiovascular and cardiometabolic risk factors, health-related quality of life, symptoms of anxiety and depression, sleep quality and immune function will be investigated. Gold-standard techniques and a variety of analyses will be performed to access the potential mechanisms involved in response to this intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Lupus Erythematosus
Keywords
Life style, Behavioral intervention, Cardiovascular risk, Life quality
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Experimental group and no intervention group (usual care group)
Masking
Outcomes Assessor
Masking Description
The researcher responsible for performing the blood flow measurement will be blinded to the allocation of groups
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Living well with Lupus Group
Arm Type
Experimental
Arm Description
A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
Arm Title
Usual Care Group
Arm Type
No Intervention
Arm Description
This group will receive all regular medical care and advice healthy
Intervention Type
Behavioral
Intervention Name(s)
Living well with Lupus
Intervention Description
The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
Primary Outcome Measure Information:
Title
Risk cardiovascular score
Description
assessed by measures of five standard variables (HDL cholesterol, triglycerides, fasting blood glucose, waist circumference and blood pressure - average of systolic and diastolic blood pressures). Z-score = [(50 - HDL cholesterol)/sd + (triglycerides - 150)/ sd] + [(fasting blood glucose - 100)/ sd] + [(waist circumference - 88)/ sd] + [(blood pressure - 115)/ sd]. Higher score values represent higher risk. *sd: standard deviation. Higher Z-score represent higher risk.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Body mass index (BMI)
Description
assessed by weight (kg) and height (m) that will be combined to report BMI in kg/m^2
Time Frame
6 months
Title
Waist circumference (cm)
Description
assessed by measuring tape positioned at the midpoint between the last floating vertebra and the iliac crest.
Time Frame
6 months
Title
Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides
Description
assessed by blood sample analysis and combined to determine lipid profile
Time Frame
6 months
Title
Insulin sensitivity
Description
assessed by oral glucose tolerance test (OGTT)
Time Frame
6 months
Title
Systolic and Diastolic blood pressure
Description
assessed by auscultatory method with mercury sphygmomanometer
Time Frame
6 months
Title
Physical activity level
Description
assessed by thigh-mounted accelerometer (ActivPAL™ micro)
Time Frame
6 months
Title
Food consumption
Description
assessed by three 24-hour food recall in non-consecutive days (being one of the days on the weekend)
Time Frame
6 months
Title
Visceral fat
Description
assessed by tomography
Time Frame
6 months
Title
Peak oxygen consumption, as assessed by a cardiopulmonary exercise test
Time Frame
6 months
Title
Endothelial function
Description
assessed by flow-mediated vasodilatation (FMD)
Time Frame
6 months
Title
Disease activity
Description
The activity of the disease, which will be impaired by safety, will be assessed by the presence of anti-dsDNA, using the ELISA technique and confirmation by indirect immunofluorescence in Crithidia luciliae and assessed by the questionnaire Systemic lupus erythematosus disease activity index 2000 (SLEDAI-2000). Total score ranges from 0 to 105. Higher scores represent higher disease activity.
Time Frame
6 months
Title
Damage index
Description
assessed by Systemic Lupus International Collaborating Clinics/ American College of Rheumatology - Damage Index. Total score range from 0 (no damage) to 46 (maximum damage).
Time Frame
6 months
Title
Global health status
Description
assessed by the Visual Analogic Scale (0 and 10 scale). Higher values represent worst global health status.
Time Frame
6 months
Title
Patients' perceptions of the intervention
Description
assessed by focus group. A semi-structured script composed of open questions about intervention positive and negative points, barriers for physical activity practice and changes in food consumption, perceptions of health improvement or worsening (physical and psychological aspects), well-being, motivation to maintain the changes made, perspectives regarding health and disease.
Time Frame
6 months
Title
Quality of Life assesment assessed by the Short-Form Health Survey-36 (SF36) [followed by its scale information in the Description]
Description
maximum score is 100, with higher scores representing better life quality
Time Frame
6 months
Title
Quality of Life assessed by Systemic Lupus Erythematosus Quality of Life Questionnaire ( SLEQOL) [followed by its scale information in the Description]
Description
score ranges from 40 to 280 with higher scores represent worst life quality.
Time Frame
6 months
Title
Physical functioning assessed by Timed-Stands
Description
evaluates the maximum number of stand-ups that a subject could perform from a standard height (i.e., 45 cm) armless chair within 30 s
Time Frame
6 months
Title
Physical functioning assessed by Timed Up-and-Go
Description
evaluates the time required for the subject to rise from a standard arm chair, walk towards a line drawn on the floor three meters away, turn, return, and sit back down again
Time Frame
6 months
Title
Physical functioning assessed by handgrip test
Description
Patients will be instructed to squeeze the dynamometer as hard as possible
Time Frame
6 months
Title
Fatigue
Description
assessed by Fatigue Scale (FACIT). The final score can vary from 0 to 52, where higher final score representing higher level of fatigue.
Time Frame
6 months
Title
Anxiety
Description
assessed by sub-scale of Hospital Anxiety and Depression Scale (HADS), called HADS-A. Total score ranges from 0 to 21. Where higher final score representing higher level.
Time Frame
6 months
Title
Depression
Description
assessed by sub-scale of Hospital Anxiety and Depression Scale (HADS), called HADS-D. Total score ranges from 0 to 21. Where higher final score representing higher level.
Time Frame
6 months
Title
Sleep quality assessed by data obtained from Actigraph (Actigraph GT3x)
Description
Data from actigraph will come as these measures: Total Sleep Time (hours/day), Sleep Efficiency (%), Sleep Onset Latency (min), and Wake After Sleep Onset (min), and this data will be considered to determine the sleep quality.
Time Frame
6 months
Title
C-reactive protein (PCR)
Description
assessed by analysis of blood sample
Time Frame
6 months
Title
Erythrocyte sedimentation rate
Description
assessed by analysis of blood sample
Time Frame
6 months
Title
Inflammatory markers (blood biochemistry)
Description
assessed by serum cytokines
Time Frame
6 months
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Only female participants will be eligible
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women between 18 and 65 years old diagnosed with systemic lupus erythematosus
one or more high cardiovascular risk factors
SLEDAI score ≤ 4
Treatment with prednisone at a dosage <10 mg/d and treatment with hydroxychloroquine in a stable dose
Exclusion Criteria:
another rheumatic diseases (except for secondary Sjogren's syndrome)
participation in structured exercise training programs and/or prescriptive diets
illiterate or with diagnosed cognitive disorders or musculoskeletal impairments that potentially compromise understanding and participation in the intervention
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bruno Gualano, PhD
Phone
+551130618789
Email
gualano@usp.br
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
we can share the individual data of the participants if the request is reasonable
Learn more about this trial
Healthy Lifestyle Intervention in Patients With Systemic Lupus Erythematosus: The Living Well With Lupus Study
We'll reach out to this number within 24 hrs